| Biological Sciences | Lifetime | 275 | NL 7 | 99.96 |
| Biological Sciences | 2021-2025 | 17 | NL 1 | 99.98 |
| Medical and Health Sciences | 2021-2025 | 414 | NL 12 | 99.91 |
| Genetics | Lifetime | 23 | NL 1 | 99.94 |
| Epidemiology | Lifetime | 200 | NL 2 | 99.75 |
| Surgery | Lifetime | 881 | NL 15 | 99.16 |
| Immunology | Lifetime | 731 | NL 16 | 97.67 |
| Gastroenterology | Lifetime | 360 | NL 8 | 94.30 |
| Genetics | 2021-2025 | 6 | NL 1 | 99.96 |
| Epidemiology | 2021-2025 | 62 | NL 1 | 99.65 |
| Immunology | 2021-2025 | 41 | NL 2 | 99.15 |
| Surgery | 2021-2025 | 157 | NL 4 | 99.07 |
| Oncology | 2021-2025 | 546 | NL 14 | 92.31 |
| Medical Genetics | 2021-2025 | 227 | NL 6 | 89.36 |
| Emergency Medicine | 2021-2025 | 319 | NL 5 | 70.98 |
| Inflammatory Bowel Disease | Lifetime | 11 | NL 1 | 99.94 |
| Microscopic Colitis | Lifetime | 10 | NL 1 | 99.93 |
| Biosimilars and Bioanalytical Methods | Lifetime | 7 | NL 2 | 99.67 |
| Autoimmune and Inflammatory Disorders | Lifetime | 7 | NL 1 | 99.92 |
| Eosinophilic Esophagitis | Lifetime | 22 | NL 1 | 99.78 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 35 | NL 2 | 99.74 |
| Diverticular Disease and Complications | Lifetime | 24 | NL 3 | 99.56 |
| Helicobacter pylori-related gastroenterology studies | Lifetime | 161 | NL 4 | 99.19 |
| Liver Diseases and Immunity | Lifetime | 72 | NL 3 | 99.12 |
| Autoimmune and Inflammatory Disorders Research | Lifetime | 154 | NL 14 | 98.85 |
| Celiac Disease Research and Management | Lifetime | 102 | NL 5 | 98.17 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 536 | NL 15 | 98.59 |
| Diagnosis and treatment of tuberculosis | Lifetime | 162 | NL 5 | 97.79 |
| Pregnancy and Medication Impact | Lifetime | 246 | NL 11 | 97.11 |
| Gastrointestinal Tumor Research and Treatment | Lifetime | 724 | NL 17 | 96.54 |
| Anorectal Disease Treatments and Outcomes | Lifetime | 423 | NL 27 | 96.30 |
| Pharmaceutical studies and practices | Lifetime | 841 | NL 50 | 94.98 |
| IL-33, ST2, and ILC Pathways | Lifetime | 617 | NL 15 | 94.55 |
| Gastrointestinal Bleeding Diagnosis and Treatment | Lifetime | 406 | NL 7 | 94.24 |
| Hidradenitis Suppurativa and Treatments | Lifetime | 725 | NL 25 | 71.46 |
| Whipple's Disease and Interleukins | Lifetime | 977 | NL 20 | 48.80 |
| Inflammatory Bowel Disease | 2021-2025 | 3 | NL 1 | 99.95 |
| Microscopic Colitis | 2021-2025 | 3 | NL 1 | 99.94 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 2 | NL 1 | 99.60 |
| Diverticular Disease and Complications | 2021-2025 | 5 | NL 2 | 99.14 |
| Eosinophilic Esophagitis | 2021-2025 | 12 | NL 1 | 99.46 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 13 | NL 1 | 99.56 |
| Helicobacter pylori-related gastroenterology studies | 2021-2025 | 18 | NL 1 | 98.97 |
| Autoimmune and Inflammatory Disorders | 2021-2025 | 5 | NL 1 | 99.54 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 33 | NL 3 | 98.83 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 150 | NL 6 | 98.12 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 31 | NL 2 | 95.71 |
| Celiac Disease Research and Management | 2021-2025 | 23 | NL 1 | 97.11 |
| Liver Diseases and Immunity | 2021-2025 | 54 | NL 2 | 97.88 |
| Pregnancy and Medication Impact | 2021-2025 | 66 | NL 2 | 95.27 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 111 | NL 3 | 93.30 |
| Pharmaceutical studies and practices | 2021-2025 | 199 | NL 17 | 89.43 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 714 | NL 27 | 91.63 |
| Appendicitis Diagnosis and Management | 2021-2025 | 366 | NL 22 | 84.27 |
| Anorectal Disease Treatments and Outcomes | 2021-2025 | 347 | NL 30 | 86.69 |
| Gastrointestinal Tumor Research and Treatment | 2021-2025 | 704 | NL 26 | 85.38 |
| Intraperitoneal and Appendiceal Malignancies | 2021-2025 | 389 | NL 48 | 84.17 |
| Psoriasis: Treatment and Pathogenesis | 2021-2025 | 760 | NL 21 | 84.48 |
| Diagnosis and treatment of tuberculosis | 2021-2025 | 393 | NL 7 | 77.15 |
| Sphingolipid Metabolism and Signaling | 2021-2025 | 290 | NL 7 | 74.77 |
| Gastrointestinal Bleeding Diagnosis and Treatment | 2021-2025 | 458 | NL 4 | 76.30 |
| Intestinal Malrotation and Obstruction Disorders | 2021-2025 | 600 | NL 46 | 62.22 |
| Hidradenitis Suppurativa and Treatments | 2021-2025 | 627 | NL 17 | 57.32 |